Gritstone Oncology, Inc. (GRTS) financial statements (2021 and earlier)

Company profile

Business Address 5959 HORTON STREET, SUITE 300
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments171128153
Cash and cash equivalents1705752
Short-term investments170101
Prepaid expense112
Other current assets000
Other undisclosed current assets322
Total current assets:175131158
Noncurrent Assets
Operating lease, right-of-use asset2123
Property, plant and equipment222729
Restricted cash and investments111
Other noncurrent assets  0
Other undisclosed noncurrent assets221
Total noncurrent assets:465332
TOTAL ASSETS:222184190
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities171010
Accounts payable1055
Accrued liabilities111
Employee-related liabilities654
Deferred revenue35
Debt 3 
Contract with customer, liability5
Other undisclosed current liabilities72 
Total current liabilities:272015
Noncurrent Liabilities
Long-term debt and lease obligation1921 
Operating lease, liability1921
Liabilities, other than long-term debt91015
Deferred revenue810
Contract with customer, liability13
Deferred rent credit  1
Other liabilities0 0
Other undisclosed noncurrent liabilities  10
Total noncurrent liabilities:283125
Total liabilities:555040
Stockholders' equity
Stockholders' equity attributable to parent167134149
Common stock000
Additional paid in capital493355276
Accumulated other comprehensive income (loss) 0(0)
Accumulated deficit(326)(221)(126)
Total stockholders' equity:167134149
TOTAL LIABILITIES AND EQUITY:222184190

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:441
Operating expenses(110)(102)(67)
Operating loss:(106)(98)(66)
Net loss:(106)(98)(66)
Other undisclosed net income attributable to parent141
Net loss available to common stockholders, diluted:(105)(94)(65)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(106)(98)(66)
Comprehensive loss:(106)(98)(66)
Other undisclosed comprehensive income, net of tax, attributable to parent141
Comprehensive loss, net of tax, attributable to parent:(105)(94)(65)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: